MANAGEMENT OF THE COVID-19 HEALTH CRISIS: A SURVEY IN SWISS

HOSPITAL PHARMACIES

Running title: Swiss hospital pharmacies COVID-19 management

Laurence Schumacher, PharmD, PhD[1,2*]; Yassine Dhif, PharmD[3*]; Pascal Bonnabry, PharmD,

PhD[1,3]; Nicolas Widmer, PharmD, PhD[1,2]

[1] Specialised Centre for Emergency and Disaster Pharmacy, Institute of Pharmaceutical

Sciences of Western Switzerland, School of Pharmaceutical Sciences, University of Geneva,

Geneva, Switzerland

[2] Pharmacy of the Eastern Vaud Hospitals, Rennaz, Switzerland

[3] Pharmacy of Geneva University Hospitals, Geneva, Switzerland

[*] These two authors contributed equally

Corresponding author

PD Dr Nicolas Widmer

Institute of Pharmaceutical Sciences of Western Switzerland

School of pharmaceutical sciences

University of Geneva, CMU

1, rue Michel-Servet

1211 Genève 4

Email: Nicolas.Widmer@unige.ch

Phone: +41 58 773 48 14

Word count: 3411 and 29 references

Keywords: Disasters; Response; COVID-19; lessons learn; Pandemics; Health Facilities;

Hospital Pharmacy, Service

ABSTRACT

Background: The COVID-19 pandemic has put a lot of strain on health systems since 2020. A

review of the Swiss hospital pharmacies responses during the first wave was performed to

improve the quality of the pharmaceutical management of future health crises.

Methods: An electronic survey was sent to all head of hospital pharmacies in Switzerland. The

questionnaire was organized into eleven clusters of questions and covered many topics

regarding the management of the first wave of COVID-19. Data collection was conducted from

May to June, 2020.

Results: Analyses were performed with 43 responses (66%) out of 65 questionnaires sent (at

least one answer per questionnaire). 41% (17/41) of pharmacies had existing standard operating

procedures or pandemic plans and 95% of them (39/41) created a steering committee to manage

the crisis. 67% (29/43) created new activities to respond to the specific needs of the crisis. 67%

(26/39) created new drug lists for: COVID-19-specific treatments (85% of pharmacies; 22/26),

sedatives (81%; 21/26), anaesthetics (77%; 20/26) and antibiotics (73%; 19/26). Drug

availability in COVID-19 wards was managed by increasing existing stocks (54% of

pharmacies; 22/41) and creating extra storage space (51%; 21/41). Two drugs generated the

most concern about shortages: propofol (49% of pharmacies; 19/39) and midazolam (44%;

17/39). Remdesivir stocks even ran out in 26% of pharmacies (10/39). Specific new documents

were drafted to respond to medical needs with regards to drug administration (28% of

pharmacies; 12/43), drug preparation (28%; 12/43) and treatment choices (23%; 10/43).

Conclusions: Swiss hospital pharmacies encountered many challenges related to the COVID-19

crisis and had to find solutions quickly, effectively and safely. The survey highlights the key

role played by Hospital Pharmacy's in many aspects during the pandemic by providing

logistical and clinical support to medical and care teams. The lessons and experiences outlined

could be used to improve the quality of the preparation for similar future events.

KEY POINTS

► The COVID-19 pandemic generated unprecedented global demand for specific drugs, hand

sanitizer solution, and other therapeutic products, particularly in critical care settings,

highlighting the essential role of hospital pharmacists in such crises.

► Key COVID-19 responses at the hospital pharmacy level included staff flexibility with

regards to changes in roles and procedures, communication, teamwork and solidarity, and the

need to prepare business continuity plans and management dashboards► Managing and facing

complex pandemic response reveals the importance of involving hospital pharmacists in

pandemic response steering committees at many levels. The lived experiences during the

pandemic could have been reviewed and evaluated to raise awareness and guide future policy

responses for when the next crisis occurs.

ABBREVIATION LIST

COVID-19: Coronavirus disease 2019

EpidA: Swiss Federal Act on Epidemics

F: French-speaking region of Switzerland

G: German-speaking region of Switzerland

GSASA: Swiss Society of Public Health Administration and Hospital Pharmacists

I: Italian-speaking region of Switzerland

ICU: Intensive Care Unit

MERS-CoV: Middle East respiratory syndrome coronavirus

R: Romansh-speaking region of Switzerland

SARS-CoV-1: Severe acute respiratory syndrome coronavirus 1

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2

Swissmedic: Swiss Agency for Therapeutic Products

WHO: World Health Organisation

BACKGROUND

The year 2020 was marked by the Coronavirus Disease 2019 (COVID-19) pandemic, which will certainly go down in history. In December 2019, the city of Wuhan, capital of Hubei Province in China, reported the first cases of pneumonia due to a new, previously unknown coronavirus[1]. In February 2020, the World Health Organisation (WHO) officially named this new virus SARS-CoV-2 and the disease it caused COVID-19, short for Coronavirus Disease 2019. Human-to-human transmission has been confirmed[2].

The first case of COVID-19 in Switzerland was confirmed on 25 February 2020 in the canton of Ticino. On 28 February, in accordance with the Federal Act on Epidemics (EpidA), the Swiss Federal Council declared a "special situation" by presenting the COVID-19 Ordinance, and it prohibited gatherings of more than 1,000 people. At the beginning of March 2020, the number of cases detected became increasingly important in Europe, mainly in Italy, where the European outbreak started[3]. On 11 March, the WHO declared the COVID-19 epidemic to be a pandemic. On 12 March, Switzerland had the third highest prevalence of COVID-19 of any European country affected by the coronavirus. On 16 March, the Swiss Federal Council declared an "extraordinary situation" (Art. 7 EpidA) and updated Ordinance 2 with new measures: the closure of non-essential businesses (including restaurants and leisure facilities) and partial border closures[4]. Progressively, it also mobilised several conscript formations of the Swiss Armed Forces to assist the cantons with healthcare, logistics and security[5]. The Swiss healthcare system did not reach saturation despite Switzerland being one of the most highly affected countries in the world, with prevalence increasing from 7.2 to 357 cases per 100,000 inhabitants between 9 March and 19 May 2020[6]. As of summer 2022, Switzerland is facing already his seventh wave of the COVID-19 pandemic, resulting in a total of 55'396 hospitalizations and 13'436 deaths due to a COVID-19 infection since the beginning of the pandemic.

The services of hospital pharmacies were in high demand especially during this first wave of the pandemic because of their critical responsibility for the supply of therapeutic products.

However, in the context of disasters, pharmacists were often forgotten or disregarded as a

necessary disaster health care team member. In fact, pharmacist's roles in disaster did not

become of significant interest in the literature until the events of September 11, 2001[7]. Prior to

2001, accepted roles for pharmacists generally focused on their contributions to logistics and

supply chain management[8]. In addition to this established role in supply chain logistics,

several roles for pharmacists in disaster health management in general[9, 10] and pandemic[11]

in particular have been identified mainly following disasters such Hurricane Katrina in 2005[12]

or bushfire disaster in Australia in 2019[13].

Since the beginning of the COVID-19 pandemic, many studies have been published on the

public health response, but few focus specifically on hospital pharmacy response and the role of

pharmacists[14, 15, 16, 17, 18]. Some described however already the response in Europe but

with not so many details.[19, 20] All publications reporting in detail on the experience during

the pandemic are essential to improve the quality of the preparation for such an event in the

future.

The present study's objective was thus to obtain an overview of the actions undertaken by

hospital pharmacies across Switzerland as they responded to the challenges encountered during

the first wave of the COVID-19 pandemic and to provide information and attitudes to improve

the quality of the pharmaceutical management in future health crises.

METHOD

A closed survey using a web-based open questionnaire, multicentre, designed on the

SurveyMonkey® platform (SurveyMonkey, San Mateo, CA, USA) was conducted. Various

questions in the survey emerged from initial feedbacks from fellow hospital pharmacists.

Several practical problems experienced daily have made it possible to suggest the challenges

faced by hospital pharmacists during the COVID-19 crisis.

All the questions were organised into eleven sections: general information about the respondent,

the hospital pharmacies and the hospital, management of this crisis, human resources

management, drugs used primarily in intensive care units (ICUs), drugs used specifically for

treating SARS-CoV-2, drug management in COVID-19 care units (including ICUs), hygiene,

support for medical and care teams, care management for patients recovering from COVID-19,

other problems encountered, and future perspectives. Altogether, it consisted of 67 questions

and used adaptive design to create a custom pathway through the survey depending on the

respondent's answers. We used conditional branching to create a custom path through the

survey, depending on the respondent's answer. Therefore, not all participants needed to answer

every question. Each question can therefore have a different number of respondents. To manage

the non-response error and these "missing data", each question uses its own denominator. Most

of the questions were multiple-choice and allowed multiple answers. All questions are available

in appendix I.

The questions were reviewed and validated by the steering committee of the Swiss Society of

Public Health Administration and Hospital Pharmacists (GSASA) and the survey was tested on

the web platform by two head pharmacists (GSASA members) before fielding of all other

members. The large majority of acute hospital pharmacists in Switzerland are members of

GSASA.

Data were collected between 19 May and 19 June 2020 via an anonymous questionnaire sent

out by individually by email (to protect unauthorized access) to all the country's head hospital

pharmacists affiliated to the GSASA (corresponding at 65 people; inclusion criteria), to avoid

duplicate entries (to prevent "multiple participation" of participants). Email reminders were sent

out at two, three and four weeks after the first mailing. Data were analysed using standard

descriptive statistics. Means and proportions were calculated using the total number of

participants responding to a given question. Responses left blank were coded as missing data

and handled using a list wise deletion method. The respondents who answered only general

information were excluded.

The research protocol, which did not imply patient data collection, has been presented to the

Cantonal Research Ethics Committee Geneva, which waived an ethical oversight.

RESULTS

GENERAL INFORMATION

Responses of 43 participants were obtained out of 65 surveys sent, which represented a

participation rate of 66%. The number of answers for each question are available on the

appendix The participants completed the survey in about 39 min. in average. Switzerland's

population is spread across four linguistic regions: German-speaking(G), French-speaking(F),

Italian-speaking(I) and Romansh-speaking(R). Most of our study participants worked in

German-speaking regions (79%; 34/43) and only one of 43 participants (2%) worked in each of

the Romansh-speaking and Italian-speaking regions. The remaining participants worked in

French-speaking regions (19%; 8/43). To simplify the analysis, French- and Italian-speaking

participants were grouped together(F/I), and so were German- and Romansh-speaking head

hospital pharmacists(G/R).

MANAGEMENT OF THE CRISIS

During the first wave of the COVID-19 outbreak, 41% (17/41) of hospital pharmacies had

previously prepared internal standard operating procedures regarding disaster management

plans whether general disaster Standard operating procedures (17%; 7/41) or specific pandemic

plans (24%; 10/41); 18% (7/39) of hospital pharmacies had a business continuity plan prior to

the pandemic (38% F/I, 3/8; 13% G/R, 4/31); and an equal number of hospital pharmacies

(18%; 7/39) created a plan especially to manage the pandemic. Of those hospital pharmacies

which had a pandemic/disaster management plan prior to the COVID-19 crisis, 56% (9/16) did

however not a business continuity plan have. This percentage rose to 70% (16/23) among

hospital pharmacies which did not have a pandemic/crisis management plan prior to the

COVID-19 crisis. The details of the business continuity plans are listed in Table 1.

Table 1. Business continuity plan	Total n (%)*	German n (%)‡	French n (%)§
All key functions and tasks were listed, with the names of the persons responsible	9 (22)	4 (12)	5 (63)
Tasks which could, in great part, be carried out at home (teleworking) were identified	9 (22)	4 (12)	5 (63)
Tasks which could be put on hold and whose usual staff could be moved to other roles were identified	8 (20)	4 (12)	4 (50)
All key functions and tasks had pre-identified replacements or deputies	7 (17)	3 (9)	4 (50)
Job functions at risk of severe contamination were identified (direct contact with other persons or clients, etc.)	7 (17)	3 (9)	4 (50)
Tasks which must imperatively be carried out within the pharmacy itself were identified	6 (15)	4 (12)	2 (25)
Some staff were trained for new roles and tasks before any staff shortages	5 (12)	2 (6)	3 (38)
Some staff were trained for new roles and tasks because of absences or illness among the usual persons responsible	2 (5)	0 (0)	2 (25)
Key posts were assigned dual leadership	2 (5)	1 (3)	1 (13)
Tasks which could be carried out by external companies or contractors were identified	2 (5)	1 (3)	1 (13)

* Among 41 answers. ‡ Among 33 answers (German/Romansh) **§** Among 8 answers (French/Italian)

Most hospital pharmacies (95%; 39/41) created a steering committee to manage the crisis. This

was often composed of the head pharmacist (61%; 25/41), a member of the pharmaceutical

logistics unit (34%; 14/41), a representative from outside the pharmacy (32%; 13/41), a

representative of the hospital's general crisis management team (27%; 11/41), a representative

from the cantonal authorities (22%; 9/41) and a member of the clinical pharmacy unit or the

pharmaceutical assistance unit (20%; 8/41). Among hospital pharmacies with a disaster

management plan, 53% (9/17) created paper or electronic dashboards or another management

tool (i.e. an Excel® file) especially for the COVID-19 crisis, but 24% (4/17) had no dashboards

at all. The remaining 24% (4/17) used previously prepared dashboards. Of the hospital

pharmacies without prior Standard operating procedures, 61% (14/23) created dashboards

specifically to manage the crisis. The panels of those dashboards are listed in Table 2. It is

worth noting that only two hospital pharmacies (5%; 2/43) had a panel of risks management.

Table 2. Information present on dashboard panels for the management of the COVID-19 crisis	Total n (%)*	German n (%)‡	French n (%)§
Overview of essential stock items requiring monitoring	21 (49)	15 (44)	6 (67)
Summary report of the hospital situation	16 (37)	12 (35)	4 (44)
Situation at the pharmacy	16 (37)	11 (32)	5 (56)
Situation overview	13 (30)	9 (26)	4 (44)
General problems affecting the pharmacy	10 (23)	7 (21)	3 (33)
Number of pharmacy employees	8 (19)	5 (15)	3 (33)
Forward/provisional planning	8 (19)	4 (12)	4 (44)
Problems faced by different units in the pharmacy	7 (16)	4 (12)	3 (33)
Important contacts	7 (16)	5 (15)	2 (22)
List of key functions	6 (14)	6 (18)	0 (0)
Journal of events	5 (12)	2 (6)	3 (33)
Emergency measures	4 (9)	2 (6)	2 (22)
Problem assessment (synthesis of problems encountered)	2 (5)	0 (0)	2 (22)
Pending issues	2 (5)	0 (0)	2 (22)
Risks management	2 (5)	1 (3)	1 (11)
Task completion status	2 (5)	1 (3)	1 (11)
Schedule of the next situation updates	2 (5)	0 (0)	2 (22)

* Among 43 answers. ‡ Among 34 answers (German/Romansh) § Among 9 answers (French/Italian)

HUMAN RESOURCES MANAGEMENT

Hospital guidelines were the main source of human resource management advice during the

COVID-19 outbreak (70%, 30/43). The main changes in human resource management carried

out are summarised in Table 3. Role changes occurred in the following fields: disinfectants

manufacturing (collecting bottles, production, and filling done by pharmacists and volunteers),

administrative work for ICUs (done by pharmacy technicians), pharmacists also acted as

pharmacy technicians on wards and logisticians in drug distribution, with 9% (4/43) of hospital

pharmacies reassigning pharmacists to these tasks.

Table 3. Human resources management	Total n (%)*	German n (%)‡	French n (%)§
New activities had to be created to respond to the specific needs of the crisis	29 (67)	22 (65)	7 (78)
Activities had to be reorganised	27 (63)	21 (62)	6 (67)
Staff with functions that permitted it were asked to work from home	25 (58)	19 (56)	6 (67)
Only essential activities were maintained (non-urgent activities were shut down)	24 (56)	19 (56)	5 (56)
Staff at risk were moved to safer environments (either home or restricted to low-risk activities)	20 (47)	12 (35)	8 (89)
Normal activities were maintained during the crisis	20 (47)	16 (47)	4 (44)
Pharmacy telephone numbers were rerouted, and access to the pharmacy computer network was provided to pharmacists working from home	11 (26)	6 (18)	5 (56)
Extra staff were recruited from among volunteers	11 (26)	8 (24)	3 (33)
Others**	8 (19)	8 (24)	0 (0)
A dedicated pandemic response team was set up	8 (19)	4 (12)	4 (44)
Extra staff were recruited from among civil protection units	7 (16)	2 (6)	5 (56)
Substitute or replacement staff were organised (especially in key functions)	7 (16)	5 (15)	2 (22)
Shift teams were kept together to avoid any mixing of staff	5 (12)	4 (12)	1 (11)
Sick leave was compensated	5 (12)	5 (15)	0 (0)
Extra staff were recruited from among civilian service personnel	4 (9)	3 (9)	1 (11)
Extra staff were recruited from among former employees	3 (7)	3 (9)	0 (0)
Extra staff were recruited from among retired hospital pharmacies' staff	2 (5)	1 (3)	1 (11)
No changes in practice	2 (5)	2 (6)	0 (0)
A business continuity plan was developed at the start of the crisis	1 (2)	0 (0)	1 (11)
Extra staff were recruited from the Swiss Armed Forces	0 (0)	0 (0)	0 (0)
Free telephone numbers were set up for maintaining contact with staff, clients and suppliers	0 (0)	0 (0)	0 (0)

* Among 43 answers ‡ Among 34 answers (German/Romansh) §Among 9 answers (French/Italian)

**e.g. extra staff from other hospitals, free parking provided by local authorities to avoid public transport use, staff

presence minimised in order to minimise virus transmission risk, paid leave for pharmacy technicians because of

closed inpatients units.

DRUGS MANAGEMENT

To limit risks of any shortages, 56% of hospital pharmacies (23/41) had anticipated reserve

supplies (100% F/I, 8/8; 45% G/R, 15/33). A list of drugs used for treating COVID-19 patients

and their supply problems is compiled in Figure 1. 34% of hospital pharmacies (14/41) imported

drugs from the European Union (63% F/I, 5/8; 27% G/R, 9/33), but only 7% (3/41) (25% F/I,

2/8; 3% G/R, 1/33) had to import drugs from a country outside those usually used. 10% (4/41)

of hospital pharmacies asked a statistician to provide stock forecasts (13% F/I, 1/8; 9% G/R,

3/33). Less than a quarter of hospital pharmacies (22%; 9/41) managed never to run out of drug

stocks at all (13% F/I, 1/8; 24% G/R, 8/33). Drug stocks on wards treating COVID-19 patients

were sometimes managed by assigning dedicated pharmacy technicians (29%; 12/41). 76% of

hospital pharmacies (31/41) managed the risk of shortages by strictly monitoring the drugs

dedicated to COVID-19 patients (63% F/I, 5/8; 79% G/R, 26/33). 63% of hospital pharmacies

(26/41; 75% F/I, 6/8; 61% G/R, 20/33) found alternative drugs and proposed these instead to

medical staff or their healthcare institution. Alternatives were proposed to guarantee the

continuity of care and save the stocks. 27% of hospital pharmacies (11/41) had to prepare

alternative protocols in partnership with medical or care staff in case these potential shortages

occurred (50% F/I regions, 4/8; 21% G/R regions, 7/33). 51% of hospital pharmacies (20/39)

created specific drug lists for care units treating COVID-19 patients (75% F/I, 6/8; 65% G/R,

20/31). Types of drugs contained in these lists are summarised in Table 4.

Drug availability in COVID-19 wards was managed by increasing existing stocks (54% of

pharmacies; 22/41) and creating extra storage space (51%; 21/41).

Table 4. Drugs used for treating COVID-19 patients		
Therapeutic class	n (%)	Drugs
COVID-19 treatments	22 (83)	Lopinavir/ritonavir (Kaltera®) and equivalents, hydroxychloroquine (Plaquenil®) and equivalents, remdesivir (Veklury®), tocilizumab (Actemra®)
Sedatives	21 (81)	Dexmedetomidine, lorazepam, midazolam
Anaesthetics	20 (77)	Etomidate, fentanyl, ketamine, propofol, remifentanil, sufentanil, suxamethonium
Antibiotics	19 (73)	Amikacin, amoxicillin, azithromycin, ceftriaxone, cefuroxime, imipenem/cilastatin, meropenem, piperacillin/tazobactam, posaconazole

Curares	15 (58)	Atracurium, cisatracurium, rocuronium
Electrolytes	11 (42)	ND
Perfusions	10 (38)	Heparin, insulin
Laxatives	4 (15)	ND
Others	3 (12)	Anticoagulation drugs, G-CSF and nutritional supplements

ND: No data

Drug production units in 24% of hospital pharmacies (10/41) reconditioned drugs (38% F/I

regions, 3/8; 21% G/R regions, 7/33). 10% of hospital pharmacies (4/41) had to produce drugs

(25% F/I, 2/8; 6% G/R, 2/33). The main drugs manufactured by hospital pharmacies were

hydromorphone, midazolam, morphine, ketamine, fentanyl (all parenteral forms) and

hydroxychloroquine (HCQ) suspension.

SUPPORT FOR MEDICAL AND CARE TEAMS

49% of hospital pharmacies (19/39) worked together with other clinical teams in their hospital

to provide appropriate treatment management protocols for COVID-19 patients arriving at the

ICU. hospital pharmacies played a key role in many aspects of the COVID-19 pandemic by

providing clinical and logistical support to medical and care teams. Detailed support activities

for medical and care teams are listed in Table 5.

Table 5. Support activities implemented by hospital pharmacies for medical and care units			
	Total n (%)*	German n (%)‡	French n (%)§
Questions were dealt with by the usual pharmaceutical hotline	28 (68)	21 (64)	7 (88)
Specific documents were drawn up to respond to medical and care staff's needs regarding drug administration	12 (29)	8 (24)	4 (50)
Specific documents were drawn up to respond to medical and care staff's needs regarding drug preparation	12 (29)	9 (27)	3 (38)
A pharmacist was present in the ICU to support medical staff	10 (24)	4 (12)	6 (75)
Specific documents were drawn up to respond to medical and care staff's needs regarding treatment choices	10 (24)	6 (18)	4 (50)
A pharmacy technician was present in the ICU to help resupply wards with drugs	9 (22)	6 (18)	3 (38)

A pharmacist was present in the ICU to support care staff	8 (20)	3 (9)	5 (63)
A pharmacy technician was present in other care units treating COVID-19 patients to help resupply wards with drugs	8 (20)	5 (15)	3 (38)
A pharmacist was present in other care units treating COVID-19 patients to support medical staff	7 (17)	3 (9)	4 (50)
A pharmacist was present in other care units treating COVID-19 patients to support nurses	4 (10)	1 (3)	3 (38)
A pharmacy technician was present in other care units treating COVID-19 patients to help nurses withdraw drugs from their care unit's drug stocks	2 (5)	1 (3)	1 (13)
A dedicated pharmacy hotline was set up to answer care staff's questions linked to treating COVID-19	2 (5)	0 (0)	2 (25))
A pharmacy technician was present in the ICU to help nurses withdraw drugs from their care unit drug stocks	1 (2)	0 (0)	1 (13)
No specific support activities were proposed	7 (17)	7 (21)	0 (0)
A pharmacy technician was present in other care units treating COVID-19 patients to help nurses prepare drugs	1 (2)	1 (3)	0 (0)
A pharmacy technician was present in the ICU to help nurses prepare drugs (e.g. preparation of injectables)	0 (0)	0 (0)	0 (0)

* Among 41 answers ‡ Among 33 answers (German/Romansh) §Among 8 answers (French/Italian)

In general, clinical pharmacy services also provided tables with product characteristics and

monitored every prescription closely (checking for interactions, contraindications, and correct

dosage).

OTHER ACTIVITIES AND PROBLEMS REPORTED IN WARDS

20% of hospital pharmacies (8/41) implemented other support activities, e.g. a pharmacist and a

pharmacy technician were present on weekends to support medical staff (stand-by service at the

ICU). They were also in close communication with the ICU head. Pharmacy technicians took

over some ICU administrative work or the centralised preparation of prefilled syringes for

syringe pumps. Syringes (ketamine, noradrenaline, etc.) for ICUs were produced in hospital

pharmacies instead of by nurses. Medication reviews for patient treatments were also carried

out. One head hospital pharmacist sat on an interdisciplinary physicians' committee

(emergency, ICU, COVID ward, pneumology, cardiology and infectious diseases). Regarding

problems involving the administration of drugs used mainly in ICUs, 12% of hospital

pharmacies (5/41) experienced a lack of syringe pumps (25% F/I, 2/8; 9% G/R, 3/33) and 10%

(4/41) experienced a lack of injectable drugs (13% F/I, 1/8; 9% G/R, 3/33). Among the hospital

pharmacies which faced problems involving the administration of drugs used mainly in ICUs,

60% (9/15) designed alternative drug administration protocols to save on the number of syringe

pumps or injectable formulations used, 33% (5/15) managed the distribution and allocation of

drug administration material, and 7% (1/15) developed protocols for remdesivir administration.

DISCUSSION

Most head hospital pharmacists answered our survey, with a repartition in the different regions

of Switzerland corresponding relatively to the speaking parts of Switzerland. The French-

speaking hospital pharmacies were mainly well prepared. The half of hospital pharmacies

moved at-risk employees to safer environments. Moreover, a small part of the participating

hospital pharmacies set up a dedicated pandemic response team and provided pharmaceutical

support to the medical and nurse's team in the clinical wards. Some hospital pharmacies

assigned a pharmacy team to daily medication stock controls and management in clinical wards

treating COVID-19 patients. At the central pharmacy, to limit the risks of shortages, reserve

supplies had been planned for in slightly more than half of hospital pharmacies.

Human resource reorganisation was an important issue to guarantee the continuity of the

activity during the pandemic. In some countries(21), hospital pharmacies reorganised their

activities to limit their human resource risks: roles were redistributed and non-pharmacist staff

were used to assist in manufacturing units and answer the phone(22). Other hospital pharmacies

encouraged work from home and physical distancing(23). Personal fears regarding

contamination risk originating in nursing homes or between colleagues was an issue in some

hospital pharmacies and should be considered in any future pandemic preparedness plans.

During crisis management, the presence of a team leader is crucial(24, 25). The pandemic

preparedness plan recommends that organisations create a "pandemic team" to manage their

response to an outbreak(26). However, in our study, the pandemic's teams were composed

mainly of the head pharmacist and a representative of the pharmaceutical logistics unit (namely

a pharmacist in charge of the logistics at hospital pharmacies). A recent hospital pharmacy

study, highlighted the difficulty for head pharmacist to lead the crisis management.

Furthermore, the leader and his team, must identify quickly the problem and then make

decisions, implement management tools, and communicate effectively. For this purpose,

dashboards can be helpful (27). In the present survey, among hospital pharmacies with a disaster

management plan, the half-created paper/electronic dashboards or other management tools (i.e.

an Excel® file) especially for the COVID-19 crisis. The recent study mentioned underlined also

the importance of preparing and drill it. Indeed, having management plan is a precious starting

point but it is not enough on its own (27). The main point is to test and train it (28). In contrast,

fewer hospital pharmacies had prepared a human resource continuity plan. For 18% few a plan

existed before the pandemic occurred and for the remaining 18%, the plan was specially created

to manage the pandemic: only a small part of German-speaking.hospital pharmacies, but mainly

of French-speaking hospital pharmacies. As numbers of contaminations grew during the crisis, a

third of French-speaking hospital pharmacies created specific human resource continuity plans,

and much more than although only few parts of the German-speaking hospital pharmacies did.

This reflected the fact that French-speaking regions suffered more contaminations than German-

speaking regions, which thus felt less need to create those plans(29).

Higher incidences of stockouts were to be expected during a pandemic; thus, drug stocks in care

units treating COVID-19 patients were managed by either increasing existing stocks or creating

extra storage space. Drug management in wards treating COVID-19 patients generated some

adjustments to routine roles. At the beginning of the pandemic, it was very difficult for hospital

pharmacies to anticipate which drugs would be used the most and thus which had to be ordered,

bought, and stocked in sufficient quantities. This raises the question of risk perception, which

seems to have been different in French- and German-speaking regions regarding the number of

COVID-19 patients expected. It is noteworthy that some of hospital pharmacies experienced no

stockouts at all. French-speaking regions made more preventive stocks, but also experienced

relatively more stockouts. This might be explained by the fact that French-speaking regions

were more affected by the pandemic.

A scoping review of pharmacists' roles during the pandemic suggested that hospital pharmacies

provided drug information to healthcare professionals as part of their daily activities(30). This

significant review was the first to highlight that counselling healthcare professionals and

patients on drugs were the main action carried out by hospital pharmacists during the COVID-

19 pandemic. Indeed, the COVID-19 outbreak revealed new opportunities for hospital

pharmacists as they stepped into new roles (greater involvement in thinking about treatment

choices, counselling about drugs saving strategy), suggesting that fully integrated, inter-sectoral,

inter-professional collaboration is necessary to face crises and public health emergencies

effectively(31). Our study highlights the key role played by hospital pharmacies' in many

aspects of the COVID-19 pandemic by providing clinical and logistical support to medical and

care teams. Clinical and hospital pharmacists promoted safe, effective medication management

among COVID-19 patients and participated in guideline development in partnership with care

providers (physicians, infectiologists, and other specialists) and pandemic management experts.

Our study found that hospital pharmacists went in clinical wards to support nurses, and hospital

pharmacies physicians. The roles of the pharmacists in the wards were varied and included,

among others, proposing alternatives to guarantee the continuity of care and save the stocks. In

addition, specific COVID-19 documents were drawn up to respond to medical needs with

regards to drug administration, preparation, and treatment choices. Indeed, by working together

with other clinicians to provide appropriate treatment management protocols for COVID-19

patients arriving at the ICU, pharmacists underline their important role during a pandemic.

These roles are supported by international disaster health community who states that

pharmacists should have more roles in disasters, in addition to logistics, including stockpile

management, vaccination, health and medication education, ensuring continuity of medication

care, highlighting the important role for pharmacist in disaster management teams(7, 9).

Future improvements in crisis response will require action at many levels: in hospital

pharmacies, hospitals, cantons and nationally. To prevent stock outs, the manufacture of drugs

and medical devices within Switzerland should be promoted. Generally, for subsequent waves

of the pandemic in Switzerland, the following measures are recommended to hospital

pharmacists: 1) update Standard operating procedures and emergency planning procedures; 2)

develop worst-case scenario plans for dealing with supply chain and train them (e.g. table top,

preparedness exercises etc.); 3) refine business continuity plans; 4) maintain dashboards and

concepts used in the first wave (e.g. communication concept); 5) ensure that protection

measures and hygiene and social distancing rules are respected; 6) anticipate and ensure

minimal pharmacy stock needs by stocking "pandemic inventories" of drugs, disinfectants and

Personal Protective Equipment; 7) monitor and evaluate drug use, availability and shortages; 8)

exchange directly with stakeholders (wards, public administration, etc.).

In the future, it would be also interesting to repeat this questionnaire to evaluate the response

after several waves of COVID-19. Thus, we could measure if the response changes with

experience and see if hospital pharmacies having already been strongly impacted by the first

wave of the pandemic had an easier response to the next wave.

The present survey had however some limitations. The first is that only 66% head hospital

pharmacists who received the questionnaire answered it despite two reminders. Nevertheless,

this rate remains high and can be considered representative of pharmacies working in acute

hospitals. Pharmacists who were not affiliated to the GSASA were not requested to participate

because, as they generally do not work in acute care hospitals (but rather in psychiatric clinics

or small private hospitals), they were potentially less affected by the imperatives of COVID-19

crisis management. Also, some participants failed to complete the whole survey, making

comparisons between some answers difficult in a few cases.

CONCLUSIONS

This was the first national-level study on the interventions undertaken by hospital pharmacies in acute care hospitals across Switzerland in response to the vast new challenges encountered during the COVID-19 pandemic. Swiss hospital pharmacies encountered many challenges and had to find solutions quickly, effectively and safely. The survey highlights the key role played by hospital pharmacy's in many aspects during the pandemic by providing logistical and clinical support to medical and care teams. Altogether, the findings illustrate the wide range of activities undertaken by hospital pharmacies with regards to crisis management, but they identified major areas of concern that emerged due to this public health crisis. The lessons and experiences outlined could be used to improve the quality of the preparation for similar future events in Switzerland such as in any hospital pharmacies in Europe or in other parts of the World.

DECLARATIONS

ETHICS APPROVAL STATEMENT

The research protocol, which did not imply patient data collection, has been presented to the Cantonal Research Ethics Committee Geneva, which waived an ethical oversight

CONSENT FOR PUBLICATION

Not applicable

AVAILABILITY OF DATA AND MATERIALS

All questions of the survey are available in appendix I. Detailed results of surveys for each question can be asked to the corresponding author.

CONFLICTS OF INTEREST/COMPETING INTERESTS

The authors have declared no potential conflicts of interest.

FUNDING AND ACKNOWLEDGMENT

This study was funded by the Swiss Federal Department of Defence, Civil Protection and Sport, through the Centre of Competence for Military and Disaster Medicine. The survey was reviewed by the steering committee of the Swiss Society of Public Health Administration and Hospital Pharmacists, especially PD Dr Johnny Benney, past president.

CONTRIBUTORSHIP STATEMENT

LS: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft

YD: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft

PB: Conceptualization, Funding acquisition, Methodology, Supervision, Writing – review & editing

NW: Conceptualization, Funding acquisition, Methodology, Supervision, Writing – review & editing

REFERENCES

1. Han Q, Lin Q, Jin S, You L. Coronavirus 2019-nCoV: A brief perspective from the front line. J Infect. 2020;80(4):373-7.

2. World Health Organisation (WHO). World Health Organisation Website: COVID-19 [Available from: https://www.who.int/fr/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it.

3.   Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? The Lancet.

2020;395(10231):1225-8.

4.   Swiss Federal Office of Public Health (FOPH). Maladie à coronavirus 2019 (COVID-19):

Rapport sur la situation épidémiologique en Suisse et dans la Principauté de Liechtenstein.

Bern, Switzerland.2020.

5.   Droz R. Opération CORONA 20. Rev Mil Suisse. 2020(4):5-7.

6.   Swiss Federal Office of Public Health (FOPH). COVID-19. Situation Suisse: Répartition

par canton, âge et sexe. Bern, Switzerland.2020.

7.   Ford H, von Waldner T, Perri M, 3rd. Pharmacists' Roles in Post-September 11th Disasters:

A Content Analysis of Pharmacy Literature. J Pharm Pract. 2014;27(4):350-7.

8.   Ford H, Dallas CE, Harris C. Examining roles pharmacists assume in disasters: a content

analytic approach. Disaster Medicine Public Health Preparedness. 2013;7(6):563-72.

9.   Watson KE, Tippett V, Singleton JA, Nissen LM. Disaster Health Management: Do

Pharmacists Fit in the Team? Prehospital and disaster medicine. 2019:1-8.

10. McCourt E, Singleton J, Tippett V, Nissen L. Disaster preparedness amongst pharmacists

and pharmacy students: a systematic literature review. The International journal of

pharmacy practice. 2021;29(1):12-20.

11. European Association of Hospital Pharmacists (EAHP). COVID-19: Hospital Pharmacists

fighting at the frontline for patients during the pandemic. 2022.

12. Young D. Pharmacists play vital roles in Katrina response: more disaster-response

participation urged. American journal of health-system pharmacy : AJHP : official journal

of the American Society of Health-System Pharmacists. 2005;62(21):2202, 4, 9,16.

13. Moss A, Green T, Moss S, Waghorn J, Bushell MJ. Exploring Pharmacists' Roles during

the 2019-2020 Australian Black Summer Bushfires. Pharmacy (Basel, Switzerland).

2021;9(3).

14. Moye RA, Mason K, Flatt A, Faircloth B, Livermore J, Brown B, et al. Emergency

preparation and mitigation for COVID-19 response in an integrated pharmacy practice

model. American journal of health-system pharmacy : AJHP : official journal of the

American Society of Health-System Pharmacists. 2021.

15. Tan SL, Zhang BK, Xu P. Chinese pharmacists' rapid response to the COVID-19 outbreak.

American journal of health-system pharmacy : AJHP : official journal of the American

Society of Health-System Pharmacists. 2020;77(14):1096-7.

16. Shrestha A, Rajbhandari P, Bajracharya S. Hospital Preparedness for Outbreak at Patan

Hospital: Lesson Learnt from COVID-19. Journal of Nepal Health Research Council.

2020;18(1):142-3.

17. Badreldin HA, Atallah B. Global drug shortages due to COVID-19: Impact on patient care

and mitigation strategies. Research in Social & Administrative Pharmacy. 2020.

18. Ahuja T, Merchan C, Arnouk S, Cirrone F, Dabestani A, Papadopoulos J. COVID-19

pandemic preparedness: A practical guide from clinical pharmacists' perspective. American

journal of health-system pharmacy : AJHP : official journal of the American Society of

Health-System Pharmacists. 2020;77(18):1510-5.

19. Paudyal V, Cadogan C, Fialova D, Henman MC, Hazen A, Okuyan B, et al. Provision of

clinical pharmacy services during the COVID-19 pandemic: Experiences of pharmacists

from 16 European countries. Res Social Adm Pharm. 2020.

20. European association of hospital pharmacists (EAHP). EAHP Survey on the future crisis

preparedness of hospital pharmacies. 2021.

21. Adam JP, Khazaka M, Charikhi F, Clervil M, Huot DD, Jebailey J, et al. Management of

human resources of a pharmacy department during the COVID-19 pandemic: Take-aways

from the first wave. Research in social & administrative pharmacy : RSAP.

2021;17(1):1990-6.

22. Zuckerman AD, Patel PC, Sullivan M, Potts A, Knostman M, Humphreys E, et al. From

natural disaster to pandemic: A health-system pharmacy rises to the challenge. American

journal of health-system pharmacy : AJHP : official journal of the American Society of

Health-System Pharmacists. 2020.

23. Siddiqui MA, Abdeldayem A, Dayem KA, Mahomed SH, Diab MJ. Pharmacy leadership

during emergency preparedness: Insights from the Middle East and South Asia. American

journal of health-system pharmacy : AJHP : official journal of the American Society of

Health-System Pharmacists. 2020.

24. Carresi AL. The 2004 Madrid train bombings: an analysis of pre-hospital management.

Disasters. 2008;32(1):41-65.

25. Carron P-N, Dami F, Frei I, Niquille M, Pasquier M, Vallotton L, et al. Médecine

d'urgence préhospitalière. Médecine & Hygiène ed2013.

26. Swiss Federal Office of Public Health (FOPH). Plan de pandémie, Manuel pour la

préparation des entreprises. 3rd ed2019.

27. Schumacher L, Senhaji S, Gartner BA, Carrez L, Dupuis A, Bonnabry P, et al. Full-scale

simulations to improve disaster preparedness in hospital pharmacies. BMC Health Serv

Res. 2022;22(1):853.

28. Pryor E, Heck E, Norman L, Weiner B, Mathews R, Black J, et al. Integrated decision-

making in response to weapons of mass destruction incidents: development and initial

evaluation of a course for healthcare professionals. Prehospital Disaster Medicine.

2006;21(1):24-30.

29. Swiss Federal Office of Public Health (FOPH). Maladie à coronavirus 2019 (COVID-19):

Rapport sur la situation épidémiologique en Suisse et dans la Principauté de Liechtenstein -

semaine 25 (15 au 21.6.2020). Bern, Switzerland.2020.

30. Visacri MB, Figueiredo IV, Lima TM. Role of pharmacist during the COVID-19

pandemic: A scoping review. Research in social & administrative pharmacy : RSAP.

2021;17(1):1799-806.

31. Bragazzi NL, Mansour M, Bonsignore A, Ciliberti R. The role of hospital and community

pharmacists in the management of COVID-19: Towards an expanded definition of the

roles, responsibilities, and duties of the pharmacist. Pharmacy. 2020;8(3).